RU2004113452A - Способы и композиции, относящиеся к лентивирусным векторам с ограниченной экспрессией и к их применениям - Google Patents
Способы и композиции, относящиеся к лентивирусным векторам с ограниченной экспрессией и к их применениям Download PDFInfo
- Publication number
- RU2004113452A RU2004113452A RU2004113452/13A RU2004113452A RU2004113452A RU 2004113452 A RU2004113452 A RU 2004113452A RU 2004113452/13 A RU2004113452/13 A RU 2004113452/13A RU 2004113452 A RU2004113452 A RU 2004113452A RU 2004113452 A RU2004113452 A RU 2004113452A
- Authority
- RU
- Russia
- Prior art keywords
- promoter
- cells
- vector according
- vector
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (33)
1. Лентивирусный вектор, содержащий трансген, расположенный под контролем специфического в отношении клеточного типа, тканеспецифического или индуцируемого промотора.
2. Вектор по п.1, где клеточные типы выбраны из группы зрелых кровяных клеток, нейтрофилов, моноцитов, гранулоцитов, нейронов, клеток легких, мышечных клеток, клеток печени, клеток поджелудочной железы, клеток эндотелия, клеток сердца, клеток кожи, клеток стромы костного мозга и клеток глаза.
3. Вектор по п.2, где транскрипция трансгена специфична, главным образом, в отношении моноцитов и/или гранулоцитов.
4. Вектор по п.1, дополнительно содержащий центральный полипуриновый тракт (сРРТ), расположенный выше экспрессирующей кассеты, предпочтительно, где сРРТ содержит нуклеотидную последовательность SEQ ID NO:1, и более предпочтительно, дополнительно содержащий множественные уникальные участки клонирования, расположенные выше и/или ниже сРРТ.
5. Вектор по п.1, дополнительно определенный как самоинактивирующийся вектор (SIN), предпочтительно, где LTR-область приведена, по существу, в транскрипционно неактивное состояние посредством делеций в U3-области 3'-концевой LTR, более предпочтительно, где осуществлены делеции нуклеотидов в положениях от -418 до -18 относительно к границе U3-Р-области.
6. Вектор по п.1, где промотор представляет собой промотор gp91-phox, промотор gp47-phox, промотор CD11b, промотор бета-глобина, промотор МНС класса II, промотор фактора свертывания IX, промотор инсулина, промотор PDX1, промотор CD4 и промотор CD2.
7. Вектор по п.1, дополнительно содержащий, по меньшей мере, одну последовательность энхансера, и, предпочтительно, последовательность энхансера выбрана из группы SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 и SEQ ID NO:7.
8. Вектор по п.1, дополнительно содержащий центральный полипуриновый тракт (сРРТ), предпочтительно, где, по меньшей мере, одна последовательность энхансера расположена выше и/или ниже сРРТ.
9. Вектор по п.1, где промотор способен стимулировать экспрессию трансгена при отношении сигнал/шум, составляющем примерно от 10 до 200, предпочтительно, примерно от 40 до 200 и, более предпочтительно, примерно от 150 до 200.
10. Вектор по п.1, где промотор способен стимулировать экспрессию трансгена в ответ на действие активатора транскрипции, причем активатор транскрипции, предпочтительно, представляет собой γ-IFN.
11. Вектор по п.1, где трансген представляет собой gp91-phox, gp47-phox, эритропоэтин, интерлейкин, колониестимулирующий фактор, интегрин αllbβ, ген множественной лекарственной резистентности, противовирусный ген, ген, кодирующий фактор свертывания крови VIII, ген, кодирующий фактор свертывания крови IX, рецептор Т-клеточного антигена, рецептор В-клеточного антигена, одноцепочечное антитело (ScFv), TNF, γ-интерферон, CTLA4, В7, Melana, MAGE, маркерный ген, люциферазу или GFP.
12. Вектор по п.1, дополнительно содержащий последовательность посттранскрипционной регуляции, расположенную так, что она стимулирует экспрессию трансгена, причем интрон расположен в ориентации, противоположной геномному транскрипту вектора, или элемент посттранскрипционной регуляции, предпочтительно, элемент посттранскрипционной регуляции вируса гепатита североамериканского лесного сурка (WRPE) или элемент посттранскрипционной регуляции вируса гепатита В (HPRE).
13. Рекомбинантный лентивирусный вектор, содержащий
(a) экспрессирующую кассету, содержащую трансген, расположенный под контролем промотора, который активен в плане стимуляции выявляемой транскрипции трансгена в человеческой клетке; и
(b) центральный полипуриновый тракт (сРРТ), расположенный выше экспрессирующей кассеты.
14. Вектор по п.13, где вектор способен трансдуцировать примерно от 20 до 80% клеток.
15. Вектор по п.13, где вектор способен трансдуцировать примерно от 60 до 80% клеток.
16. Вектор по п.13, дополнительно содержащий множественные уникальные участки клонирования, расположенные выше или ниже сРРТ.
17. Вектор по п.13, дополнительно определенный как самоинактивирующийся вектор (SIN).
18. Вектор по п.13, где LTR-область приведена, по существу, в транскрипционно неактивное состояние посредством делеций в US-области 3'-концевой LTR.
19. Вектор по п.13, где промотор представляет собой промотор gp91-phox, промотор gp47-phox, промотор CDllb, промотор EF1-a, промотор PGK, промотор бета-глобина, промотор МНС класса II, промотор фактора свертывания IX, промотор инсулина, промотор PDX1, промотор CD4 и промотор CD2.
20. Вектор по п.13, дополнительно содержащий, по меньшей мере, одну последовательность энхансера.
21. Вектор по п.13, где промотор способен стимулировать экспрессию трансгена в конкретных клеточных типах.
22. Вектор по п.21, где конкретные клеточные типы выбраны из группы зрелых кровяных клеток, нейтрофилов, моноцитов, гранулоцитов, нейронов, клеток легких, мышечных клеток, клеток печени, клеток поджелудочной железы, клеток эндотелия, клеток сердца, клеток кожи, клеток стромы костного мозга и клеток глаза.
23. Вектор по п.13, где трансген представляет собой gp91-phox, gp47-phox, эритропоэтин, интерлейкин, колониестимулирующий фактор, интегрин αllbβ, ген множественной лекарственной резистентности, противовирусный ген, ген, кодирующий фактор свертывания крови VIII, ген, кодирующий фактор свертывания крови IX, Т-клеточный рецептор антигена, В-клеточный рецептор антигена, одноцепочечное антитело (ScFv), TNF, γ-интерферон, CTLA4, В7, Melana, MAGE, маркерный ген, люциферазу или GFP.
24. Вектор по п.13, дополнительно содержащий последовательность посттранскрипционной регуляции, расположенную так, что она стимулирует экспрессию трансгена.
25. Вектор по п.24, где последовательность посттранскрипционной регуляции представляет собой интрон, расположенный в экспрессирующей кассете, или элемент посттранскрипционной регуляции.
26. Вектор по п.25, где элемент посттранскрипционной регуляции представляет собой элемент посттранскрипционной регуляции вируса гепатита североамериканского лесного сурка (WRPE) или элемент посттранскрипционной регуляции вируса гепатита В (HPRE).
27. Клетка-хозяин, трансдуцированная вектором по любому из пп.1-26, предпочтительно, человеческая кроветворная клетка-предшественник и, более предпочтительно, CD34+-клетка.
28. Способ трансдукции человеческой кроветворной стволовой клетки in vitro, предусматривающий взаимодействие популяции человеческих клеток, содержащей кроветворные стволовые клетки, с вектором по любому из пп.1-26 в условиях, позволяющих осуществить трансдукцию человеческих кроветворных клеток-предшественников в указанной популяции указанным вектором.
29. Способ по п.28, где популяция человеческих кроветворных клеток-предшественников содержит СD34+-клетки.
30. Способ по п.28, где популяцию клеток обрабатывают, чтобы стимулировать пролиферацию клеток без существенной потери плюрипотентности стволовых клеток.
31. Способ по п.28, где экспрессию трансгена проводят с помощью активатора, индуцирующего промотор.
32. Применение клетки по п.27 или человеческой кроветворной стволовой клетки, трансдуцированной в соответствии со способом по любому из пп.28-31, для приготовления лекарственного препарата для инфузии человеку или животному.
33. Применение по п.32, где лекарственный препарат дополнительно содержит активатор, индуцирующий промотор, предпочтительно, где активатор вводят отдельно от трансдуцированной клетки.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32659301P | 2001-10-02 | 2001-10-02 | |
US60/326,593 | 2001-10-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2004113452A true RU2004113452A (ru) | 2005-10-10 |
RU2305708C2 RU2305708C2 (ru) | 2007-09-10 |
Family
ID=23272874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2004113452/13A RU2305708C2 (ru) | 2001-10-02 | 2002-09-30 | Рекомбинантный лентивирусный вектор, клетка-хозяин, трансдуцированная лентивирусным вектором, способ ее трансдукции и применение |
Country Status (12)
Country | Link |
---|---|
US (4) | US7198950B2 (ru) |
EP (1) | EP1438075A4 (ru) |
JP (1) | JP2005504539A (ru) |
KR (1) | KR20040054699A (ru) |
CN (1) | CN1606456A (ru) |
AU (1) | AU2002343458B2 (ru) |
CA (2) | CA2462628C (ru) |
IL (1) | IL161229A0 (ru) |
NZ (1) | NZ532060A (ru) |
RU (1) | RU2305708C2 (ru) |
WO (1) | WO2003029412A2 (ru) |
ZA (1) | ZA200402527B (ru) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003268546A1 (en) * | 2002-09-06 | 2004-03-29 | Massachusetts Institute Of Technology | Lentiviral vectors, related reagents, and methods of use thereof |
WO2004054512A2 (en) * | 2002-12-13 | 2004-07-01 | Genetix Pharmaceuticals, Inc. | Therapeutic retroviral vectors for gene therapy |
WO2004098531A2 (en) * | 2003-05-05 | 2004-11-18 | Virxsys Corporation | Increased transduction using abc transporter substrates and/or inhibitors |
US20070202505A1 (en) * | 2003-09-08 | 2007-08-30 | Alex Chenchik | Methods for gene function analysis |
JP2006254872A (ja) * | 2005-03-18 | 2006-09-28 | Kenzaburo Tani | 幹細胞分化の促進方法 |
US20070054872A1 (en) * | 2005-08-24 | 2007-03-08 | Mirus Bio Corporation | Regulatable or conditional expression systems |
EP1835032A1 (en) * | 2006-03-14 | 2007-09-19 | Université de Liège | A self-inactivating recombinant lentiviral vector for the inhibition of HIV replication |
WO2008105604A1 (en) * | 2007-02-27 | 2008-09-04 | Avixgen Inc. | Recombinant mammalian cell for screening a substance preventing and treating aids and screening method using the same |
KR100987004B1 (ko) * | 2007-02-27 | 2010-10-11 | (주) 에빅스젠 | Aids 예방 및 치료 물질 스크리닝용 재조합 포유동물세포 및 이를 이용한 스크리닝 방법 |
US20100291042A1 (en) | 2007-05-03 | 2010-11-18 | The Brigham And Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
US20110027310A1 (en) * | 2007-05-04 | 2011-02-03 | Medin Jeffrey A | Compositions and Methods for Cancer Treatment |
EP2150618B1 (en) | 2007-05-04 | 2017-10-11 | University Health Network | Il-12 immunotherapy for cancer |
EP2019134A1 (en) * | 2007-07-26 | 2009-01-28 | Vision 7 GmbH | Gene therapy of chronic granulomatous disease |
WO2009065080A1 (en) | 2007-11-16 | 2009-05-22 | San Diego State University Research Foundation | Compositions and method for manipulating pim-1 activity in circulatory system cells |
WO2009129616A1 (en) | 2008-04-21 | 2009-10-29 | Tissue Regeneration Therapeutics, Inc. | Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents |
WO2009137598A2 (en) * | 2008-05-06 | 2009-11-12 | University Of Chicago | Methods and composition for modulating hematopoietic stem cell migration |
WO2010045659A1 (en) * | 2008-10-17 | 2010-04-22 | American Gene Technologies International Inc. | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
CA2742876C (en) | 2008-11-06 | 2018-08-21 | Indiana University Research & Technology Corporation | Materials and methods to enhance hematopoietic stem cells engraftment procedures |
KR101793615B1 (ko) | 2009-04-30 | 2017-11-03 | 오스페달레 산 라파엘 에스.알.엘. | 유전자 벡터 |
PL2456858T3 (pl) * | 2009-07-20 | 2019-01-31 | Janssen Biotech, Inc | Różnicowanie ludzkich embrionalnych komórek macierzystych |
EP2508603B1 (en) * | 2009-11-19 | 2015-05-13 | National University Corporation Okayama University | System for increasing gene expression, and vector supporting said system |
CA2794196A1 (en) | 2010-03-23 | 2011-09-29 | Intrexon Corporation | Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof |
WO2011146885A2 (en) * | 2010-05-21 | 2011-11-24 | Virxsys Corporation | Compositions and methods for lentiviral expression of apoa-1 or variants thereof using spliceosome mediated rna trans-splicing |
EP2646107A2 (en) | 2010-12-01 | 2013-10-09 | Spinal Modulation Inc. | Agent delivery systems for selective neuromodulation |
CA2849045C (en) * | 2011-09-29 | 2020-11-17 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Lentiviral vectors pseudotyped with mutant baev glycoproteins |
US9963511B2 (en) * | 2011-12-22 | 2018-05-08 | Hoffmann-La Roche Inc. | Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides |
CN103638604B (zh) * | 2012-12-31 | 2016-05-04 | 深圳先进技术研究院 | 一种助行系统 |
RU2552609C1 (ru) * | 2013-10-28 | 2015-06-10 | Федеральное государственное бюджетное учреждение науки Институт молекулярной биотехнологии им. В.А. Энгельгардта Российской академии наук (ИМБ РАН) | Способ получения системы направленной доставки белковых молекул (онколитических белков) в опухолевые ткани на основе активированных лимфоцитов |
GB2526339A (en) | 2014-05-21 | 2015-11-25 | Imp Innovations Ltd | Lentiviral vectors |
EA201790533A1 (ru) | 2014-09-07 | 2017-07-31 | Селекта Байосайенсиз, Инк. | Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса, предназначенного для модулирования экспрессии генов |
CN107949640A (zh) * | 2015-07-01 | 2018-04-20 | 加利福尼亚大学董事会 | 含有反向取向人泛素c启动子的逆转录病毒载体 |
RU2646111C2 (ru) * | 2015-12-29 | 2018-03-01 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Экспрессионный плазмидный лентивирусный вектор для гетерологической экспрессии рекомбинантного человеческого белка cd44 |
US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
CN116179580A (zh) | 2016-04-20 | 2023-05-30 | 能源环境和技术研究中心O.A., M.P. | 用于增强pklr的基因表达的组合物和方法 |
CN106086077A (zh) * | 2016-07-05 | 2016-11-09 | 北京普瑞金科技有限公司 | 用于car‑t制备的慢病毒载体及其构建方法和应用 |
KR20190104194A (ko) | 2017-01-07 | 2019-09-06 | 셀렉타 바이오사이언시즈, 인크. | 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여 |
KR20230093381A (ko) * | 2017-01-09 | 2023-06-27 | 아메리칸 진 테크놀로지스 인터내셔널 인코포레이티드 | 예비-면역화 단계가 없는 hiv 면역요법 |
AU2018212002A1 (en) | 2017-01-30 | 2019-08-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant virus vectors for the treatment of glycogen storage disease |
WO2018176103A1 (en) | 2017-03-30 | 2018-10-04 | The University Of Queensland | "chimeric molecules and uses thereof" |
GB201706121D0 (en) * | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Stable cell lines for retroviral production |
WO2019075360A1 (en) | 2017-10-13 | 2019-04-18 | Selecta Biosciences, Inc. | METHODS AND COMPOSITIONS FOR MITIGATING ANTI-VECTOR VIRAL TRANSFER IGM RESPONSES |
US11642422B2 (en) | 2017-10-16 | 2023-05-09 | Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, O.A, M.P. | Lentiviral vectors for delivery of PKLR to treat pyruvate kinase deficiency |
RU2697797C2 (ru) * | 2017-12-28 | 2019-08-19 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Генетическая конструкция для индукции пролиферации периферических моноцитов in vitro |
MX2020008243A (es) | 2018-02-05 | 2020-11-24 | Ibex Biosciences Llc | Uso de pcbp1 para el tratamiento de enfermedades hiperproliferativas. |
CA3092372A1 (en) | 2018-02-26 | 2019-08-29 | AnTolRx, Inc. | Tolerogenic liposomes and methods of use thereof |
WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
EP3845656A4 (en) * | 2018-08-28 | 2022-06-15 | Pharos Vaccine Inc. | IMPROVED LENTIVIRAL VECTOR |
US20210386788A1 (en) | 2018-10-24 | 2021-12-16 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
WO2020185632A1 (en) | 2019-03-08 | 2020-09-17 | Obsidian Therapeutics, Inc. | Human carbonic anhydrase 2 compositions and methods for tunable regulation |
CN109971787A (zh) * | 2019-04-17 | 2019-07-05 | 北京美康基免生物科技有限公司 | 一种cybb慢病毒载体、慢病毒载体转染的干细胞及其制备方法和应用 |
EP3959235B1 (en) | 2019-04-26 | 2023-07-26 | Allogene Therapeutics, Inc. | Rituximab-resistant chimeric antigen receptors and uses thereof |
MX2021013163A (es) | 2019-04-28 | 2022-02-21 | Selecta Biosciences Inc | Métodos para el tratamiento de sujetos con inmunidad preexistente a vectores de transferencia viral. |
EP3966227A1 (en) | 2019-05-07 | 2022-03-16 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
EP3976802A1 (en) | 2019-05-28 | 2022-04-06 | Selecta Biosciences, Inc. | Methods and compositions for attenuated anti-viral transfer vector immune response |
EP3983449A1 (en) | 2019-06-11 | 2022-04-20 | Shire Human Genetic Therapies, Inc. | Adeno associated viral vector delivery of antibodies for the treatment of disease mediated dysregulated plasma kallikrein |
EP3983551A4 (en) * | 2019-06-14 | 2023-10-18 | The Regents Of The University Of California | CONSTRUCTION OF DNA TO TARGET THERAPEUTIC MOLECULES TO DISEASE TISSUE BY IMMUNE CELLS |
JP2022544117A (ja) * | 2019-08-07 | 2022-10-17 | アイベックス バイオサイエンシーズ, エルエルシー | 発がんを阻害しながら、誘導多能性幹細胞を作製する目的で、pcbp1を使用すること |
WO2021040736A1 (en) | 2019-08-30 | 2021-03-04 | Obsidian Therapeutics, Inc. | Tandem cd19 car-based compositions and methods for immunotherapy |
US20220348937A1 (en) | 2019-09-06 | 2022-11-03 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
AU2020361533A1 (en) | 2019-10-08 | 2022-04-28 | Trustees Of Boston College | Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins |
EP4048800A1 (en) | 2019-10-23 | 2022-08-31 | Shire Human Genetic Therapies, Inc. | Adeno-associated virus vectors based gene therapy for hereditary angioedema |
CA3161175A1 (en) * | 2019-11-12 | 2021-05-20 | The Regents Of The University Of California | Lentiviral vectors in hematopoietic stem cells to treat x-linked chronic granulomatous disease |
CN110881442A (zh) * | 2019-12-11 | 2020-03-17 | 湖南蒙生生物科技股份有限公司 | 一种使用草本生物调理粉生产生态甲鱼的方法 |
EP4114449A2 (en) | 2020-03-05 | 2023-01-11 | Neotx Therapeutics Ltd. | Methods and compositions for treating cancer with immune cells |
EP4192487A1 (en) | 2020-08-07 | 2023-06-14 | Spacecraft Seven, LLC | Plakophilin-2 (pkp2) gene therapy using aav vector |
GB202013940D0 (en) | 2020-09-04 | 2020-10-21 | Synpromics Ltd | Regulatory nucleic acid sequences |
CA3195177A1 (en) | 2020-10-07 | 2022-04-14 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i) |
US20220186252A1 (en) | 2020-12-16 | 2022-06-16 | Takeda Pharmaceutical Company Limited | Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein |
WO2022235929A1 (en) | 2021-05-05 | 2022-11-10 | Radius Pharmaceuticals, Inc. | Animal model having homologous recombination of mouse pth1 receptor |
KR20240051112A (ko) | 2021-07-01 | 2024-04-19 | 인답타 세라뷰틱스 인코포레이티드 | 조작된 자연 살해(nk) 세포 및 관련 방법 |
CN113308494A (zh) * | 2021-07-14 | 2021-08-27 | 卡瑞济(北京)生命科技有限公司 | 一种更安全的地中海贫血基因治疗载体、构建方法及其应用 |
WO2023019226A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
EP4384193A2 (en) | 2021-08-11 | 2024-06-19 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
EP4384598A1 (en) | 2021-08-11 | 2024-06-19 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
IL310691A (en) | 2021-08-11 | 2024-04-01 | Sana Biotechnology Inc | Genetically modified primary cells for allogeneic cell therapy |
US20230141563A1 (en) | 2021-10-12 | 2023-05-11 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
WO2023114918A1 (en) | 2021-12-16 | 2023-06-22 | Ludwig Institute For Cancer Research Ltd | Antisense transfer vectors and methods of use thereof |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023158836A1 (en) | 2022-02-17 | 2023-08-24 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
US20230357437A1 (en) | 2022-03-09 | 2023-11-09 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
WO2023173123A1 (en) | 2022-03-11 | 2023-09-14 | Sana Biotechnology, Inc. | Genetically modified cells and compositions and uses thereof |
WO2024007020A1 (en) | 2022-06-30 | 2024-01-04 | Indapta Therapeutics, Inc. | Combination of engineered natural killer (nk) cells and antibody therapy and related methods |
WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308236D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Dna vectors |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4682195A (en) * | 1985-09-30 | 1987-07-21 | General Electric Company | Insulated gate device with configured emitter contact pad |
US5019384A (en) | 1986-06-30 | 1991-05-28 | Massachusetts Institute Of Technology | Immunonodulating compositions and their use |
EP0266032A1 (en) | 1986-08-29 | 1988-05-04 | Beecham Group Plc | Modified fibrinolytic enzyme |
US5466468A (en) * | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
CA2051288C (en) * | 1990-09-14 | 2002-02-05 | Robert L. Martuza | Viral targeted destruction of neoplastic cells |
US5885570A (en) | 1991-01-23 | 1999-03-23 | The General Hospital Corporation | Induction of tolerance with modified immunogens |
DE4204650C1 (ru) * | 1992-02-15 | 1993-07-08 | Hoffmeister, Helmut, Dr., 4400 Muenster, De | |
DE4228457A1 (de) * | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
US5834256A (en) * | 1993-06-11 | 1998-11-10 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
US5912411A (en) | 1993-06-14 | 1999-06-15 | University Of Heidelberg | Mice transgenic for a tetracycline-inducible transcriptional activator |
FR2722208B1 (fr) * | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
US5599302A (en) * | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
US5925656A (en) * | 1995-04-10 | 1999-07-20 | Dr. Reddy's Research Foundation | Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them |
GB9510272D0 (en) * | 1995-05-22 | 1995-07-19 | Isis Innovation | Retroviral vectors |
US6013516A (en) * | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US5705629A (en) * | 1995-10-20 | 1998-01-06 | Hybridon, Inc. | Methods for H-phosphonate synthesis of mono- and oligonucleotides |
GB9525639D0 (en) * | 1995-12-15 | 1996-02-14 | Isis Innovation | Improved retroviral vectors |
US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
GB9621680D0 (en) * | 1996-10-17 | 1996-12-11 | Oxford Biomedica Ltd | Lentiviral vectors |
IL129017A0 (en) * | 1996-10-17 | 2000-02-17 | Oxford Biomedica Ltd | Retroviral vectors |
US5846225A (en) * | 1997-02-19 | 1998-12-08 | Cornell Research Foundation, Inc. | Gene transfer therapy delivery device and method |
US6017758A (en) * | 1997-02-20 | 2000-01-25 | Vanderbilt University | DMNPE caged nucleic acid and vector |
WO1998039463A2 (en) * | 1997-03-06 | 1998-09-11 | Ueberla Klaus | Lentivirus based vector and vector system |
US6207455B1 (en) * | 1997-05-01 | 2001-03-27 | Lung-Ji Chang | Lentiviral vectors |
US6531123B1 (en) | 1997-05-01 | 2003-03-11 | Lung-Ji Chang | Lentiviral vectors |
US6277633B1 (en) * | 1997-05-13 | 2001-08-21 | The University Of North Carolina At Chapel Hill | Lentivirus-based gene transfer vectors |
US5981830A (en) | 1997-05-30 | 1999-11-09 | Schering Aktiengesellschaft | Knockout mice and their progeny with a disrupted hepsin gene |
JP2002507117A (ja) * | 1997-06-04 | 2002-03-05 | オックスフォード・バイオメディカ・(ユーケイ)・リミテッド | ベクター |
US5972650A (en) | 1997-06-26 | 1999-10-26 | Brigham And Women's Hospital | Tetracycline repressor regulated mammalian cell transcription and viral replication switch |
WO1999004026A2 (en) | 1997-07-18 | 1999-01-28 | Chiron Corporation | Lentiviral vectors |
US6136597A (en) | 1997-09-18 | 2000-10-24 | The Salk Institute For Biological Studies | RNA export element |
US5994136A (en) * | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
EP1895010B1 (en) * | 1997-12-22 | 2011-10-12 | Oxford Biomedica (UK) Limited | Equine infectious anaemia virus (eiav) based vectors |
EP1045921A2 (en) | 1998-01-16 | 2000-10-25 | Chiron Corporation | Feline immunodeficiency virus gene therapy vectors |
US6084063A (en) * | 1998-02-06 | 2000-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Signal transduction inhibitors of allergic reactions |
US6218181B1 (en) * | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
WO1999051754A1 (en) * | 1998-04-02 | 1999-10-14 | Dana-Farber Cancer Institute, Inc. | Infectious pseudotyped lentiviral vectors lacking matrix protein and uses thereof |
FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
US6555342B1 (en) | 1998-06-03 | 2003-04-29 | Uab Research Foundation | Fusion protein delivery system and uses thereof |
US5989910A (en) | 1998-08-03 | 1999-11-23 | University Of Lausanne | Potent genetic switch allowing regulated gene expression in eukaryotic cells |
ATE360081T1 (de) * | 1998-08-26 | 2007-05-15 | Stuerzl Michael Prof Dr Rer Na | Guanylat-bindendes protein (gbp-1) als inhibitor der zellproliferation |
AU6139699A (en) | 1998-09-11 | 2000-04-03 | Children's Medical Center Corporation | Packaging cell lines for hiv-derived retroviral vector particles |
CA2346931C (en) * | 1998-10-01 | 2011-11-29 | University Of Southern California | Gene delivery system and methods of use |
GB9825524D0 (en) * | 1998-11-20 | 1999-01-13 | Oxford Biomedica Ltd | Vector |
DE19856463B4 (de) * | 1998-11-26 | 2006-02-02 | Heinrich-Pette-Institut | Retrovirale, mit LCMV pseudotypisierte Hybrid-Vektoren |
EP1165842A4 (en) | 1999-03-16 | 2004-07-07 | Dana Farber Cancer Inst Inc | LENTIVIRAL VECTOR SYSTEMS FOR SCREENING LARGE QUANTITIES |
US6271359B1 (en) * | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
CA2371946A1 (en) * | 1999-04-29 | 2000-11-09 | Aarhus University | Expression of heterologous genes from an ires translational cassette in retroviral vectors |
ES2447115T3 (es) | 1999-10-11 | 2014-03-11 | Institut Pasteur | Vectores para la preparación de composiciones inmunoterapéuticas |
CN101363029B (zh) | 1999-10-12 | 2016-01-13 | 巴斯德研究所 | 慢病毒三链体dna、及含有慢病毒三链体dna的载体和重组细胞 |
CA2391129A1 (en) * | 1999-11-10 | 2001-05-17 | The Uab Research Foundation | Lentiviral vector transduction of hematopoietic stem cells |
US6218186B1 (en) * | 1999-11-12 | 2001-04-17 | Trustees Of The University Of Pennsylvania | HIV-MSCV hybrid viral vector for gene transfer |
US6864085B2 (en) * | 1999-12-14 | 2005-03-08 | Novartis Ag | Bovine immunodeficiency virus (BIV) based vectors |
AU778110B2 (en) | 1999-12-14 | 2004-11-18 | Novartis Ag | Bovine immunodeficiency virus (BIV) based vectors |
AU3120601A (en) * | 2000-01-28 | 2001-08-07 | Scripps Research Inst | Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same |
JP2003526367A (ja) | 2000-03-16 | 2003-09-09 | ジェネティカ インコーポレイテッド | Rna干渉の方法とrna干渉組成物 |
WO2001092506A1 (en) | 2000-05-30 | 2001-12-06 | University Of Rochester | Siv derived lentiviral vector systems |
CA2433680A1 (en) | 2000-12-28 | 2002-08-01 | Gregory M Arndt | Double-stranded rna-mediated gene suppression |
US20020132257A1 (en) | 2001-01-31 | 2002-09-19 | Tony Giordano | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
EP1371727A4 (en) | 2001-02-22 | 2004-07-28 | Gencom Corp | RECOMBINANT GENE CONTAINING A REVERSE REPETITION SEQUENCE AND USE THEREOF |
US20030039636A1 (en) | 2001-05-01 | 2003-02-27 | Genetix Pharmaceuticals, Inc. | Novel self-inactivating (SIN) lentiviral vectors |
US20030119770A1 (en) * | 2001-08-02 | 2003-06-26 | Zhennan Lai | Intercellular delivery of a herpes simplex virus VP22 fusion protein from cells infected with lentiviral vectors |
WO2003012054A2 (en) * | 2001-08-02 | 2003-02-13 | Institut Clayton De La Recherche | Methods and compositions relating to improved lentiviral vector production systems |
ATE439041T1 (de) | 2001-09-13 | 2009-08-15 | California Inst Of Techn | Verfahren zur expression von kleinen antiviralen rna-molekülen innerhalb einer zelle |
WO2003072788A1 (en) | 2002-02-21 | 2003-09-04 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for reversibly controlling expression of target genes in cells |
-
2002
- 2002-09-30 WO PCT/US2002/031023 patent/WO2003029412A2/en active IP Right Grant
- 2002-09-30 EP EP02780402A patent/EP1438075A4/en not_active Ceased
- 2002-09-30 CA CA2462628A patent/CA2462628C/en not_active Expired - Lifetime
- 2002-09-30 AU AU2002343458A patent/AU2002343458B2/en not_active Expired
- 2002-09-30 CA CA2915676A patent/CA2915676C/en not_active Expired - Lifetime
- 2002-09-30 KR KR10-2004-7004973A patent/KR20040054699A/ko not_active Application Discontinuation
- 2002-09-30 JP JP2003532630A patent/JP2005504539A/ja active Pending
- 2002-09-30 CN CNA028241274A patent/CN1606456A/zh active Pending
- 2002-09-30 RU RU2004113452/13A patent/RU2305708C2/ru active
- 2002-09-30 NZ NZ532060A patent/NZ532060A/en not_active IP Right Cessation
- 2002-09-30 IL IL16122902A patent/IL161229A0/xx unknown
- 2002-12-02 US US10/261,078 patent/US7198950B2/en not_active Expired - Lifetime
-
2004
- 2004-03-31 ZA ZA200402527A patent/ZA200402527B/en unknown
-
2007
- 2007-02-28 US US11/680,414 patent/US8748169B2/en active Active
-
2014
- 2014-05-13 US US14/276,615 patent/US9340798B2/en not_active Expired - Fee Related
-
2016
- 2016-04-19 US US15/133,216 patent/US20170067079A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NZ532060A (en) | 2005-11-25 |
EP1438075A2 (en) | 2004-07-21 |
CA2915676A1 (en) | 2003-04-10 |
EP1438075A4 (en) | 2006-04-19 |
RU2305708C2 (ru) | 2007-09-10 |
JP2005504539A (ja) | 2005-02-17 |
ZA200402527B (en) | 2006-04-26 |
US9340798B2 (en) | 2016-05-17 |
WO2003029412A3 (en) | 2004-02-26 |
CA2915676C (en) | 2017-06-06 |
US7198950B2 (en) | 2007-04-03 |
IL161229A0 (en) | 2004-09-27 |
US20170067079A1 (en) | 2017-03-09 |
US20070196922A1 (en) | 2007-08-23 |
CA2462628A1 (en) | 2003-04-10 |
KR20040054699A (ko) | 2004-06-25 |
CN1606456A (zh) | 2005-04-13 |
US8748169B2 (en) | 2014-06-10 |
WO2003029412A2 (en) | 2003-04-10 |
US20030138954A1 (en) | 2003-07-24 |
CA2462628C (en) | 2019-08-20 |
AU2002343458B2 (en) | 2008-03-20 |
US20140335607A1 (en) | 2014-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2004113452A (ru) | Способы и композиции, относящиеся к лентивирусным векторам с ограниченной экспрессией и к их применениям | |
JP2005504539A5 (ru) | ||
Verzeletti et al. | Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors | |
JP7263327B2 (ja) | 細胞の遺伝子修飾のための非組込みdnaベクター | |
EP3414321B1 (en) | Vcn enhancer compositions and methods of using the same | |
US7056699B2 (en) | Lentiviral LTR-deleted vector | |
JP3386461B2 (ja) | 遺伝子移入法および遺伝子移入療法に用いるシトシンデアミナーゼの負の選択系 | |
Donahue et al. | Update on the use of nonhuman primate models for preclinical testing of gene therapy approaches targeting hematopoietic cells | |
AU680851B2 (en) | Progenitor B cell stimulating factor | |
NZ334522A (en) | Lentiviral vectors with the absence of TAR (TAT responsiveness) sequence | |
JP2006524051A (ja) | 両方向性合成プロモーターを備えたレンチウイルスベクターおよびその使用 | |
Lotti et al. | Transcriptional targeting of lentiviral vectors by long terminal repeat enhancer replacement | |
AU6623994A (en) | A retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and uses of said vector | |
WO1997042323A1 (en) | Treatment of human cancers with an adenovirus vector containing an interferon consensus gene | |
EP3413896A1 (en) | Vcn enhancer compositions and methods of using the same | |
Nunokawa et al. | Expression of human inducible nitric oxide synthase is regulated by both promoter and 3′-regions | |
Jayan et al. | SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional, and pol III promoters | |
SMITH | Retroviral vector-mediated gene transfer into hematopoietic cells: prospects and issues | |
WO1995019368A1 (en) | Retroviral vector particles for transducing non-proliferating cells | |
Sadelain et al. | Issues in the manufacture and transplantation of genetically modified hematopoietic stem cells | |
Jin et al. | Resistance to human immunodeficiency virus type 1 (HIV-1) generated by lentivirus vector-mediated delivery of the CCR5Δ32 gene despite detectable expression of the HIV-1 co-receptors | |
CN109609553B (zh) | 提高nk细胞靶向作用力的方法及ccr5基因的应用 | |
CA3161180A1 (en) | Lentiviral vectors in hematopoietic stem cells to treat recombination-activating gene 1 (rag1) severe combined immunodeficiency (scid) | |
EP1639001A1 (en) | Method for transplanting lymphohematopoietic cells into mammal | |
Nienhuis et al. | Gene transfer into hematopoietic cells |